AngioDynamics Solero Microwave Tissue Ablation (MTA) System: (1)Solero Applicator 29cm PG Catal...

FDA Device Recall #Z-1704-2019 — Class II — April 17, 2019

Recall Summary

Recall Number Z-1704-2019
Classification Class II — Moderate risk
Date Initiated April 17, 2019
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Angiodynamics Inc. (Navilyst Medical Inc.)
Location Glens Falls, NY
Product Type Devices
Quantity 1846

Product Description

AngioDynamics Solero Microwave Tissue Ablation (MTA) System: (1)Solero Applicator 29cm PG Catalog Number:700106003 UPN: H7877001060030 (2)Solero Applicator 29cm PG US Catalog Number:700106003US UPN:H787700106003US0 Product Usage: The Solero Microwave Tissue Ablation (MTA) System and accessories are indicated for the ablation of soft tissue during open procedures. The Solero MTA System is not intended for cardiac use.

Reason for Recall

Updated Warning Statements in the Operator's Manual/Directions for Use and Software Updates to reduce the risk of potential patient harm due to a delay in performing a procedure

Distribution Pattern

Worldwide distribution - US Nationwide distribution and countries of AE AT AU BE CA CH CL CO CZ DE DK DZ EG ES FR GB GE GR HK IE IL IN IQ IT LB LT MC MT MX NL NZ PL PT SG TH TR TW VN ZA

Lot / Code Information

Serial Numbers: (1) 16480626 17150699 17160704 17170705 17170706 17310766 17370790 17380795 17390797 17420814 17420817 17430823 17460844 17460847 17470850 5377356 (2) 17200721 17210722 17220730 17220731 17220732 17250743 17270749 17300765 17320771 17380794 17400805 17420816 17440830 17470849 5346596 5355835 5385267 5392055 5392056 5416590 5426407 5446902

Other Recalls from Angiodynamics Inc. (Navilyst Medical ...

Recall # Classification Product Date
Z-1467-2021 Class II AngioDynamics Safe Sheath Ultralite - Vascular ... Feb 22, 2021
Z-1466-2021 Class II Smart Port CT-Implantable Port Catalogue #: CT9... Feb 22, 2021
Z-0411-2020 Class II Starburst Talon Semi-Flex Electrosurgical Devic... Oct 2, 2019
Z-0504-2020 Class II BIOFLO 8F SINGLE PLASTIC FILLED; VALVED, UPN H9... Sep 18, 2019
Z-0501-2020 Class II BIOFLO 8F SINGLE PLASTIC FILLED; NON-VALVED, UP... Sep 18, 2019

Frequently Asked Questions

A software recall means the device's embedded software or firmware has a defect that could affect its performance or safety. Many software recalls are corrected through firmware updates that can be applied without physically replacing the device. For implantable devices, the update may be delivered wirelessly during a routine clinic visit. For external devices, the manufacturer may provide updated software files or replacement units. Contact your healthcare provider to determine whether your specific device and software version are affected and what action is recommended.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.